Eli Lilly and Co (Eli Lilly and Co) Deferred Tax

: $-2,341 Mil (TTM As of Dec. 2023)

View and export this data going back to 1970. Start your Free Trial

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Eli Lilly and Co's change in deferred tax for the three months ended in Dec. 2023 was $-506 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Dec. 2023 was $-2,341 Mil.

Eli Lilly and Co Deferred Tax Historical Data

The historical data trend for Eli Lilly and Co's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Deferred Tax

62.40

-134.50

-802.30

-2,185.20

-2,341.00

Eli Lilly and Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Deferred Tax																10.40	-559.40	-431.10	-844.30	-506.20

Eli Lilly and Co Deferred Tax Calculation

Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2,341 Mil.

Eli Lilly and Co Deferred Tax Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Eli Lilly and Co (Eli Lilly and Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (NYSE:LLY) » Definitions » Deferred Tax

Comparable Companies

Traded in Other Exchanges

LLY:Mexico 1LLY:Italy LLY:Germany LLY:Germany LLY:Germany LLY:Germany LLY:Switzerland LLY:Canada LILY34:Brazil LLYC:Austria LLY:Argentina

Address

Lilly Corporate Center, Indianapolis, IN, USA, 46285

Website

https://www.lilly.com

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Executives

Lilly Endowment Inc	10 percent owner	2801 NORTH MERIDIAN ST, INDIANAPOLIS IN 46208
Donald A Zakrowski	officer: Chief Accounting Officer	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Alonzo Weems	officer: SVP, ERM & CECO	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Patrik Jonsson	officer: SVP and Pres., Lilly Bio-Meds	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Anne E. White	officer: SVP & Pres-Lilly Oncology	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Eric Dozier	officer: EVP, HR & Diversity	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Jackson P Tai	director
Mary Lynne Hedley	director	C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Marschall S Runge	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Naarden Jacob Van	officer: SVP, CEO LoxoONC, Pres LlyONC	C/O ELI LILLY & CO, LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Diogo Rau	officer: SVP & CIDO	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Edgardo Hernandez	officer: SVP & Pres., Mfg. Operations	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Kimberly H Johnson	director	C/O FANNIE MAE, 1100 15TH STREET, NW, WASHINGTON DC 20005
Anat Ashkenazi	officer: SVP & CFO	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Gabrielle Sulzberger	director	450 LEXINGTON AVENUE, FLOOR 13, NEW YORK NY 10017